Learning Objectives:
Cahill:
- Review veno-occlusive disease (VOD) in allogeneic stem cell transplantation (allo-SCT)
- Discuss inotuzumab ozogamicin (INO) use in B-ALL
- Report retrospective outcomes of patients treated with INO and allo-SCT at University of Chicago
Dolezal:
- Review the evidence for immunotherapy in advanced non-small cell lung cancer (NSCLC)
- Examine recent data examining the issue of optimal immunotherapy duration for advanced NSCLC
- Discuss potential biomarkers that may assist with treatment duration decisions
Session date:
08/05/2021 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Kirk Cahill, MD & James Dolezal, MD